{"url_path":"/sec/pbm/10-k/2026/item-15","section_key":"item-15","section_title":"Item 15 CONTROLS AND PROCEDURES","topic":"sec","document":{"doc_type":"20-F","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1985062/0001213900-26-070607-index.html","accession_number":"0001213900-26-070607","cik":"0001985062","ticker":"PBM","issuer_name":"PSYENCE BIOMEDICAL LTD.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1985062/0001213900-26-070607-index.html","primary_entity_key":"0001985062","primary_entity_name":"PSYENCE BIOMEDICAL LTD."},"word_count":440,"has_tables":true,"body_markdown":"ITEM 15. CONTROLS AND PROCEDURES\n\n** **\n\nDisclosure Controls and Procedures\n\n \n\nAt the end of the period covered by this Report, an evaluation of the\neffectiveness of the design and operation of the Company’s “disclosure controls and procedures” (as such term is defined\nin Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act) was carried out by the Company’s principal executive\nofficer (the “**CEO**”) and principal financial officer (the “**CFO**”). There are inherent limitations\nto the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention\nor overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable\nassurance of achieving their control objectives. Based upon their evaluation, the Company’s CEO and CFO have concluded that, as\nof the end of the period covered by this Report, the design and operation of the Company’s disclosure controls and procedures were\neffective.* *\n\n \n\nManagement’s Annual Report on Internal Control over\nFinancial Reporting.\n\n** **\n\nOur management is responsible for establishing\nand maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed under\nthe supervision of our principal executive and principal financial officers to provide reasonable assurance regarding the reliability\nof financial reporting and the preparation of financial statements for external purposes in accordance with IFRS as issued by the IASB.\n\n \n\nBecause of its inherent limitations, internal\ncontrol over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future\nperiods are subject to the risk that controls may become inadequate due to changes in conditions, or that the degree of compliance with\nthe policies or procedures may deteriorate.\n\n \n\nUnder the supervision and with the participation\nof our management, including our principal executive and principal financial officers, we conducted an evaluation of the effectiveness\nof our internal control over financial reporting as of March 31, 2026. Based on this evaluation, our management concluded that our internal\ncontrol over financial reporting was effective as of March 31, 2026.\n\n \n\nAttestation Report of the Registered Public Accounting\nFirm.\n\n** **\n\nThis Report does not include an attestation report\nof the Company’s independent registered public accounting firm regarding internal control over financial reporting, as the Company\nis not required to obtain such an attestation pursuant to the rules of the Securities and Exchange Commission applicable to emerging growth\ncompanies and non-accelerated filers.\n\n \n\nChanges in Internal Control over Financial Reporting\n\n \n\nThere has been no change\nin the Company’s internal control over financial reporting during the fiscal year ended March 31, 2026 that has materially\naffected, or is reasonably likely to materially affect, its internal control over financial reporting.\n\n \n\n82"}